Summary
Eli Lilly and Company (LLY) filed an 8-K on July 24, 2018, to report its second quarter and three-month period results for 2018, ended June 30, 2018. The filing itself primarily serves as a notification and reference to a more detailed press release (Exhibit 99.1) containing the unaudited financial results and operational performance for the period. Investors should refer to this press release for specific financial metrics, revenue figures, and commentary on the company's performance. This report is a standard disclosure for publicly traded companies to announce quarterly earnings. The key information for investors is contained within the referenced press release, which would typically include details on earnings per share (EPS), revenue growth, segment performance, and any forward-looking guidance or strategic updates provided by the company's management. The 8-K itself does not contain these detailed financial figures but directs stakeholders to the official announcement.
Key Highlights
- 1The 8-K filing from July 24, 2018, reports Eli Lilly's financial results for the second quarter of 2018.
- 2The filing is primarily a cover document referencing an attached press release (Exhibit 99.1) for detailed financial information.
- 3The press release contains unaudited operating results for the quarter and three-month period ended June 30, 2018.
- 4This is a standard SEC filing to disseminate quarterly earnings information to the public.
- 5Investors need to consult Exhibit 99.1 for specific financial data, performance metrics, and management commentary.
- 6The filing itself does not contain the detailed financial tables or narrative of the Q2 2018 results.